/ /

Lynda Charters
Glaucoma drainage devices: Location, location, location
With glaucoma drainage devices gaining in popularity, the implantation technique must be tweaked to achieve the best results with the fewest complications.
Intraoperative aberrometry can help improve refractive results
Intraoperative aberrometry aphakic and pseudophakic readings can be comparable with careful control of surgical variables. Both readings can be useful to predict postoperative manifest refraction.
Fixed-dose combination glaucoma drug provides easy, safe IOP control
Once-daily dosing of one drop of Roclatan (Aerie Pharmaceuticals, Inc.), containing a fixed-dose combination of latanoprost and a rho kinase inhibitor and norepinephrine transport inhibitor, was clinically and statistically superior to administration of its individual components for controlling IOP in open-angle glaucoma or ocular hypertension.
Acute migraine sufferers may find relief with beta-blocker eye drops
A small case series of patients has shown that use of beta-blocker drops may be a simple and inexpensive way to eliminate pain in patients with acute migraines.
Refractive surgery for special needs children: The time is now
The time for refractive surgery for special needs children seems to be at hand, considering that advancements in laser and IOL technologies have been proven to be efficacious. Correcting a special needs child’s vision can reduce fearfulness and improve their behavioral challenges.
Acute nonarteritic CRAO: A red flag for cardiovascular risk factors
Most patients with acute nonarteritic central retinal artery occlusion have a cardiovascular risk profile, and a comprehensive medical evaluation can uncover more risk factors.
AAVhCNGB3 vectors: Potential new treatment for achromatopsia
Long-term cone functional rescue was achieved in dogs with achromatopsia AAV vectors containing codon-optimized human CNGB3 and an improved promoter, which may be a stepping stone to treating achromatopsia in humans.
Ranibizumab proves instrumental for DME patients in RIDE, RISE trials
Ranibizumab provided improvements in visual acuity and DR that were stable over the long term when the drug was administered on an as-needed regimen to patients with diabetic macular edema in the RIDE and RISE trials.
Home monitoring for AMD may have substantial impact on U.S. public health
Use of a home monitoring device to monitor patients at high risk for wet age-related macular degeneration may have a considerable public health impact over time.


View Results